Schymura et al. BMC Cancer 2010, 10:152 http://www.biomedcentral.com/1471-2407/10/152 19. McNaughton CM, Barry MJ, Zietman A, Albertsen PC, Talcott JA, Walker CE, et al.: United States radiation oncologists' and urologists' opinions about screening and treatment of prostate cancer vary by region. Urology 2002, 60:628-633. 20. Schapira MM, McAuliffe TL, Nattinger AB: Treatment of localized prostate cancer in African-American compared with Caucasian men. Less use of aggressive therapy for comparable disease. Medical Care 1995, 33:1079-1088. 21. Desch CE, Penberthy L, Newschaffer CJ, Hillner BE, Whittemore M, McClish D, et al.: Factors that determine the treatment for local and regional prostate cancer. Medical Care 1996, 34:152-162. 22. Hoffman RM, Harlan LC, Klabunde CN, Gilliland FD, Stephenson RA, Hunt WC, et al.: Racial differences in initial treatment for clinically localized prostate cancer. Results from the Prostate Cancer Outcomes Study. J Gen Intern Med 2003, 18:845-853. 23. Underwood W, De Monner S, Ubel P, Fagerlin A, Sanda MG, Wei JT: Racial/ ethnic disparities in the treatment of localized/regional prostate cancer. J Urol 2004, 171:1504-1507. 24. Morris CR, Snipes KP, Schlag R, Wright WE: Sociodemographic factors associated with prostatectomy utilization and concordance with the physician data query for prostate cancer (United States). Cancer Causes Control 1999, 10:503-511. 25. Wu XC, Chen VW, Andrews PA, Chen LS, Hsieh MC, Ahmed MN, et al.: Initial treatment patterns for clinically localized prostate cancer and factors associated with the treatment in Louisiana. J Louisiana Med Soc 2005, 157:188-194. 26. Scherr D, Swindle PW, Scardino PT: National Comprehensive Cancer Network guidelines for the management of prostate cancer. Urology 2003, 61:14-24. 27. Fowler JE Jr, Bigler SA, Bowman G, Kilambi NK: Race and cause specific survival with prostate cancer: influence of clinical stage, Gleason score, age and treatment. J Urology 2000, 163:137-142. 28. Freeman VL, Durazo-Arvizu R, Arozullah AM, Keys LC: Determinants of mortality following a diagnosis of prostate cancer in Veterans Affairs and private sector health care systems. Am J of Public Health 2003, 93:1706-1712. 29. Godley PA, Schenck AP, Amamoo MA, Schoenbach VJ, Peacock S, Manning M, et al.: Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 2003, 95:1702-1710. 30. Robertson CN, Paulson DF: Radical surgery versus radiation therapy in early prostatic carcinoma. Acta Oncol 1991, 30:239-242. 31. Potosky AL, Merrill RM, Riley GF, Taplin SH, Barlow W, Fireman BH, et al.: Prostate cancer treatment and ten-year survival among group/staff HMO and fee-for-service Medicare patients. Health Serv Res 1999, 34:525-546. 32. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL: Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008, 148:435-448. 33. Iversen P, Madsen PO, Corle DK: Radical prostatectomy versus expectant treatment for early carcinoma of the prostate. Twenty-three year follow-up of a prospective randomized study. Scand J Urol Nephrol Suppl 1995, 172(65-72):65-72. 34. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al.: A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 2002, 347:781-789. 35. Bill-Axelson A, Holmberg L, Ruutu M, Haggman M, Andersson SO, Bratell S, et al.: Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2005, 352:1977-84. 36. Bill-Axelson A, Holmberg L, Filen F, Ruutu M, Garmo H, Busch C, et al.: Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008, 100:1144-1154. 37. Wong YN, Mitra N, Hudes G, Localio R, Schwartz JS, Wan F, et al.: Survival associated with treatment vs observation of localized prostate cancer in elderly men. JAMA 2006, 296:2683-2693. 38. Lu-Yao GL, Albertsen PC, Moore DF, Shih W, Lin Y, DiPaola RS, et al.: Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA 2008, 300:173-181. 39. Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, et al.: Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: Page 15 of 15 European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 2006, 20(24):1868-1876. 40. Middleton RG, Thompson IM, Austenfeld MS, Cooner WH, Correa RJ, Gibbons RP, et al.: Prostate Cancer Clinical Guidelines Panel Summary Report on the management of clinically localized prostate cancer. J Urology 1995, 154:2144-2148. 41. Giordano SH, Kuo YF, Duan Z, Hortobagyi GN, Freeman J, Goodwin JS: Limits of observational data in determining outcomes from cancer therapy. Cancer 2008, 112:2456-2466. 42. Brawley O: Nonmedical factors in treatment selection. Urol Clin N Am 2003, 30:331-335. 43. Holmboe ES, Concato J: Treatment decisions for localized prostate cancer: asking men what's important. J Gen Intern Med 2000, 15:694-701. 44. Demark-Wahnefried W, Schildkraut JM, Iselin CE, Conlisk E, Kavee A, Aldrich TE, et al.: Treatment options, selection, and satisfaction among African American and white men with prostate carcinoma in North Carolina. Cancer 1998, 83:320-330. 45. Zeliadt SB, Ramsey SD, Penson DF, Hall IJ, Ekwueme DU, Stroud L, et al.: Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer 2006, 106:1865-1874. 46. Auvinen A, Hakama M, la-Opas M, Vornanen T, Leppilahti M, Salminen P, et al.: A randomized trial of choice of treatment in prostate cancer: the effect of intervention on the treatment chosen. BJU Int 2004, 93:52-56. 47. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, et al.: Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2000, 92:1582-1592. 48. Potosky AL, Reeve BB, Clegg LX, Hoffman RM, Stephenson RA, Albertsen PC, et al.: Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy. J Natl Cancer Inst 2002, 94:430-437. 49. Potosky AL, Davis WW, Hoffman RM, Stanford JL, Stephenson RA, Penson DF, et al.: Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: the Prostate Cancer Outcomes Study. J Natl Cancer Inst 2004, 96:1358-1367. 50. Penson DF, Litwin MS: Quality of life after treatment for prostate cancer. Current Urology Reports 2003, 4:185-195. 51. Sanda MG, Dunn RL, Michalski J, Sandler HM, Northouse L, Hembroff L, et al.: Quality of life and satisfaction with outcome among prostate- cancer survivors. N Engl J Med 2008, 358:1250-1261. 52. Hoffman RM, Hunt WC, Gilliland FD, Stephenson RA, Potosky AL: Patient satisfaction with treatment decisions for clinically localized prostate carcinoma. Results from the Prostate Cancer Outcomes Study. Cancer 2003, 97:1653-1662. 53. Warren JL, Klabunde CN, Schrag D, Bach PB, Riley GF: Overview of the SEER-Medicare Data: content, research applications, and generalizability to the United States elderly population. Medical Care 2002, 40(Supplement):IV-3-IV-18. 54. Centers for Disease Control and Prevention: Breast, Colon, and Prostate Cancer Data Quality and Treatment Patterns of Care Studies - NPCR. 2010 [http://www.cdc.gov/cancer/npcr/pocstudy.htm]. 55. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al.: Cost of Care for Elderly Cancer Patients in the United States. J Natl Cancer Inst 2008, 100:630-641. 56. Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, et al.: Cumulative cost pattern comparison of prostate cancer treatments. Cancer 2007, 109:518-527. 57. Leonhardt D: In health reform, a cancer offers an acidtest. The New York Times; 2009. Pre-publication history The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2407/10/152/prepub doi: 10.1186/1471-2407-10-152 Cite this article as: Schymura et al., Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC- NPCR Patterns of Care Study (PoC1) BMC Cancer 2010, 10:152